

## Cynata To Acquire CYP-006TK Wound Dressing Technology From TekCyte

**Melbourne, Australia; 1 July 2024:** Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has entered into an agreement with TekCyte Limited (TekCyte) to acquire wound dressing technology developed by TekCyte. This technology is a core component of Cynata’s Cymerus™ iPSC<sup>1</sup>-derived MSC<sup>2</sup> topical wound dressing product candidate, CYP-006TK, currently being investigated in an ongoing clinical trial in patients with diabetic foot ulcers (DFU).

As announced on 3 June 2021, Cynata entered into a worldwide exclusive licence agreement with TekCyte to use this technology, which is based on proprietary surface modification techniques, to produce polymer-coated dressings for the delivery of MSCs to wounds.

Cynata has now agreed to secure outright ownership of the underlying TekCyte technology utilised in CYP-006TK. In consideration of this acquisition, Cynata will issue shares to the value of \$230,000 to TekCyte. The issue of shares is subject to the completion of the assignment of the relevant intellectual property to Cynata. It is anticipated that this process will be completed within approximately one month. The Cynata shares to be issued will be priced at the volume weighted average price at which Cynata’s shares trade on the ASX during the five trading days preceding the completion of the intellectual property assignment.

Patient enrolment in the DFU trial has been completed (announced 8 April 2024), and initial results are promising. An analysis of the first 16 patients enrolled after 10 weeks’ follow-up showed a median percentage reduction in wound surface area of 87.6% in the active CYP-006TK group, compared to 51.1% in the control group (announced 26 February 2024).

**Dr Kilian Kelly, Cynata’s CEO and Managing Director, said:**

“Ownership of this technology strengthens our intellectual property position and simplifies our commercial proposition for potential partners. We are very excited by the initial results in our trial of CYP-006TK in DFU, and optimistic about the potential for this product to meaningfully change outcomes for patients.”

**Dr Tony Simula, TekCyte’s CEO and Managing Director, said:**

“TekCyte is very excited and pleased that an Australian company, Cynata, is taking ownership of our proprietary medical coating – CYPATCH – to advance the management of chronic wounds. The collaboration between our companies has been very productive and valuable and the combined wound dressing product candidate, CYP-006TK, has the potential to transform the lives of patients with diabetic foot ulcers”.

**-ENDS-**

**Authorised for release by Dr Kilian Kelly, CEO & Managing Director**

**CONTACTS:** Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, [kilian.kelly@cynata.com](mailto:kilian.kelly@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [littlebigdealconsulting@gmail.com](mailto:littlebigdealconsulting@gmail.com)

**About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges

<sup>1</sup> iPSC = induced pluripotent stem cell

<sup>2</sup> MSC = mesenchymal stem (or stromal) cell



of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.**

For personal use only